Recorded: 06 Jun 2006
It is outrageous. I mean it’s extremely high quality, it’s very well done: the selections, the topics, also that it’s five days. Originally, you think it’s a long meeting but the first one, two, three days you feel like not quite integrated yet and everybody is afraid of talking to everybody else here so we are a little shy I think, at least that’s what I feel, then after the three, four, or five days you really interact with people much more and you learn about details. And this is one of the best scientific possibilities to interact and find access to a new field. It’s very on the top, yes.
I think the way of interaction, the highest quality you can even think of - the way the books are issued, the selection of speakers. No, I don’t think it has, has changed much, which could be negative criteria, which I don’t think so. I think this is a very high up standard as it used to be and it’s one of the best things you can attend.
Well, the money normally, when the money becomes tight, people are more uptight too and don’t want to interact so much. My experience was, I always earned more than I lost, so that’s a personal statement. Normally, I’m not so much afraid of being stolen for something’s been taking away from me. I think the main thing that I experience is you learn if you talk. Science is an interactive field.
Karin Moelling currently retired professor, still affiliated with the University of Zurich and the Max-Planck-Institute for Molecular Genetics in Berlin. She studied molecular biology at the University of Berkely, Califonia. She received her PhD at the Max-Planck-Institute for Virology at Tübingen in Germany. She did two post-doctoral research at the Robert Koch Institute in Berlin (1973-1975), and at the Institute of Virology, University Giessen. In 1977 she received her Habilitation at the University of Giessen in Biophysics on "Replication of retroviruses".
From 1976 till 1981 she was the Head of Independent Research Group at Max-Planck-Institute for Molecular Genetics in Berlin, Germany, on oncogenes, proto-oncogenes, cancer and HIV. In 1993 she became the Director of Institute of Medical Virology (IMV) and Full Professor at University of Zurich in Switzerland, she held this position till 2008. Between 2008-2009 she was Fellow of Institute of Advanced Study in Berlin and between 2008-2011 she became a Group Leader, Viruses and Cancer at University of Zurich.
Her research focus on retroviruses and cancer from molecular mechanisms to drug design. She is a Member of the European Molecular Biology Organization. She received several awards e.g. SwissAward in 2007, 4 prices: Czerny Price, Richtzenhain Price, Meyenburg Price and Ansman Price. She was Selected as Heisenberg Fellow in German Science Foundation.